opnurasib

Opnurasib is a small molecule inhibitor that selectively targets the KRAS G12C mutation, an oncogenic driver found in various solid tumors, most notably non-small cell lung cancer (NSCLC). By binding to and inhibiting the mutant KRAS G12C protein, opnurasib blocks downstream signaling pathways involved in tumor cell growth, proliferation, and survival. The drug was developed by Novartis and reached up to phase III clinical trials for several indications before its development was discontinued. Opnurasib has been studied as both monotherapy and in combination with other agents such as SHP2 inhibitors. Its primary mechanism of action is direct inhibition of the KRAS G12C mutant protein[1][2][3][4][5][6].

Other names

opnurasib